Kelun-Biotech has picked up another first for its TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), after getting Chinese approval of the drug in non-small cell lung ...
It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results